Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research
  Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login  
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 904       

   Table of Contents      
INNOVATIONS
Year : 2020  |  Volume : 152  |  Issue : 7  |  Page : 258-259

Theranostic role of radiolabelled RGD peptide in the treatment of radioiodine-resistant thyroid cancer: A novel agent


Department of Nuclear Medicine, Postgraduate Institute of Medical Education & Research, Chandigarh 160 012, India

Date of Submission20-Nov-2019
Date of Web Publication25-May-2021

Correspondence Address:
Ashwani Sood
Department of Nuclear Medicine, Postgraduate Institute of Medical Education & Research, Chandigarh 160 012
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijmr.IJMR_2377_19

Rights and Permissions

How to cite this article:
Vatsa R, Sood A. Theranostic role of radiolabelled RGD peptide in the treatment of radioiodine-resistant thyroid cancer: A novel agent. Indian J Med Res 2020;152, Suppl S1:258-9

How to cite this URL:
Vatsa R, Sood A. Theranostic role of radiolabelled RGD peptide in the treatment of radioiodine-resistant thyroid cancer: A novel agent. Indian J Med Res [serial online] 2020 [cited 2021 Jul 31];152, Suppl S1:258-9. Available from: https://www.ijmr.org.in/text.asp?2020/152/7/258/316842

Patient's consent obtained to publish clinical information and images.


A 47 yr old female , a known case of papillary carcinoma thyroid, post-total thyroidectomy and radioiodine treatment (I-131, cumulative dose of 716 mCi), presented to the department of Nuclear Medicine, Postgraduate Institute of Medical Education & Research, Chandigarh, India, in June 2019, with rising serum thyroglobulin (Tg) level of 13,840 ng/ml and anti-Tg of 34.53 IU/ml. Ultrasonography of the neck revealed a lobulated heterogeneous soft tissue mass in the midline and supraclavicular region, along with bilateral subcentimetric cervical lymph nodes. There was markedly elevated serum Tg and negative whole-body radioiodine scan, also known as TENIS (Thyroglobulin Elevation with Negative Iodine Scintigraphy) syndrome [Figure 1]. The patient was evaluated with whole-body gallium-68 (Ga-68) RGD positron emission tomography/computed tomography imaging [Figure 2] for the staging and tumour tracer avidity for therapeutic potential with radionuclide therapy. RGD is an arginine–glycine–aspartic acid-based synthetic peptide targeting integrin αvβ3, which are overexpressed on endothelial cells of neovasculature and tumour cells. Lutetium-177 (Lu-177) RGD (~120 mCi) radionuclide therapy was given to the patient in view of tracer avidity in the residual/recurrent disease, and post-therapy images showed effective localization of tracer [Figure 3]. Lu-177 RGD may be a novel approach of treatment for radioiodine refractory thyroid cancer patients. Followup of the patient after four weeks of therapy showed significant reduction in serum Tg level from 13,840 ng/ml to 5,280 ng/ml with significant clinical improvement. The patient was planned for the second dose of Lu-177 RGD radionuclide therapy in view of favourable response.
Figure 1: Whole-body (anterior and posterior) low dose radioiodine diagnostic scan done after 48 h of 2 mCi of I-131administration. No abnormal tracer uptake was seen anywhere in the body apart from physiological tracer distribution.

Click here to view
Figure 2: (A) Whole-body Ga-68 RGD positron emission tomography(PET)/computed tomography (CT) (3.25 mCi) for residual disease and tracer avidity evaluation showed increased tracer uptake in the neck region (SUVmax 8.8) on maximum intensity projection (MIP) image. (B) Transaxial PET/CT and (C) computed tomography images showing tracer uptake in heterogeneously enhancing soft tissue lesion in the anterior of neck with tracheostomy tube in situ (arrows). (D and E) Another focal tracer uptake was seen in lytic lesion in the manubrium.

Click here to view
Figure 3: Whole-body (anterior and posterior) post-Lu-177 RGD radionuclide therapy images at 17 h (A and B) and 48 h (C and D) showing increased tracer uptake in neck region (arrowheads) anteriorly corresponding to tracer avid soft tissue lesion seen in pre-therapy Ga-68 RGD PET/CT scan [Figure 2]. Liver, spleen and kidneys showed physiological tracer uptake.

Click here to view


Conflicts of Interest: None.


    Figures

  [Figure 1], [Figure 2], [Figure 3]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Article Figures

 Article Access Statistics
    Viewed152    
    Printed0    
    Emailed0    
    PDF Downloaded26    
    Comments [Add]    

Recommend this journal